Torrent expands recall of losartan products, again

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Zozulya)
(Image: Getty/Zozulya)

Related tags Sartan losartan Torrent Pharmaceuticals Hetero Labs Recall

Torrent announces that it will recall batches of losartan tablets for the sixth time, after the detection of NMBA exceeding acceptable daily intake levels in latest recall.

The recall was conducted in coordination with the US Food and Drug Administration (FDA), after finished product batches were manufactured with active pharmaceutical ingredient (API) produced by Hetero Labs – a company involved in previous recalls​.

Torrent Pharmaceuticals will recall three lots of losartan potassium tablets and two lots of losartan potassium/hydrochlorothiazide tablets.

The recall was instigated after the impurity N-Methylnitrosobutyric acid (NMBA) was detected at levels above the acceptable daily intake levels, as specified by the FDA.

Torrent had previously recalled 104 lots​ of the same medicines, after NMBA was found in the API, also manufactured by Hetero.

In total, this is the sixth recall that Torrent has issued regarding losartan medications, which are used to treat hypertension and nephropathy in type 2 diabetic patients.

According to the company, it is arranging for a return of all recalled products and notifying its distributors and customers to immediately discontinue distribution of the affected lots.

The recall was announced amid a separate wave of recalls being made regarding potential contamination of ranitidine medicine, which resulted in Sandoz initiating a recall of its products​.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more